Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of 5HTP and LDOPA on CNS Excitability After SCI
NCT04000919 · Jessica M D'Amico · PHASE2/PHASE3 · suspended · last registry update 2022-10-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI left UofL and intends to reopen study at University of Alberta” | – | Registry record, Jessica M D'Amico |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-09-28Results posted on the registry: AbbVie, Cariprazine + Placebo (NCT03573297)
- 2023-09-28Also stopped (terminated): Impel Pharmaceuticals, INP105 + Placebo (NCT05163717)
- 2023-09-01Also stopped (terminated): MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, APOKYN (NCT02549573)
- 2023-06-09Phase 3 first posted: Christian Hassager, Dexamethasone + Olanzapine (NCT05895838)
- 2023-05-09Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Olanzapine 5 MG + Placebo (NCT04535141)
- 2023-05-08Results posted on the registry: Alliance for Clinical Trials in Oncology, Palonosetron Hydrochloride + Ondansetron Hydrochloride (NCT03578081)
- 2023-04-24Phase 3 first posted: Region Skane, Pramipexole (NCT05825235)
- 2023-04-18Also stopped (suspended): Shanghai Mental Health Center, Omega-3 polyunsaturated fatty acids + Olanzapine (NCT04518319)
- 2023-04-14Phase 3 first posted: Areteia Therapeutics, Dexpramipexole Dihydrochloride + Placebo (NCT05813288)
- 2023-04-10Phase 3 first posted: Xingchen Peng, 5HT3RA+Olanzapine + 5HT3RA+Olanzapine+Dexamethasone (NCT05805800)
- 2023-04-07Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Olanzapine + Haloperidol (NCT05803642)
- 2023-04-07Results posted on the registry: Pharma Two B Ltd., P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), + Placebo (NCT01968460)
- 2023-03-31Also stopped (terminated): First Affiliated Hospital of Zhejiang University, Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) + Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) (NCT04275492)
- 2023-03-21Results posted on the registry: Pharma Two B Ltd., P2B001 0.6/0.75 mg + Rasagiline 0.75 mg (NCT03329508)
- 2023-03-10Phase 3 first posted: Areteia Therapeutics, Dexpramipexole Dihydrochloride + Placebo (NCT05763121)
- 2023-02-28Phase 3 first posted: Areteia Therapeutics, Dexpramipexole Dihydrochloride + Placebo (NCT05748600)
- 2023-02-09Also stopped (withdrawn): Charite University, Berlin, Germany, Olanzapine (NCT00568672)
- 2023-02-01Also stopped (withdrawn): University of Pennsylvania, Olanzapine (NCT05179772)
- 2023-01-23Phase 3 first posted: Teva Branded Pharmaceutical Products R&D LLC, TV-44749 + Placebo (NCT05693935)
- 2023-01-19Phase 3 first posted: Alexandria University, Quatiapine + Haloperidol (NCT05690698)
- 2023-01-19Results posted on the registry: Alkermes, Inc., ALKS 3831 + Olanzapine (NCT03187769)
- 2023-01-03Phase 3 first posted: Tanta University, Empagliflozin + olanzapine (NCT05669742)
- 2022-12-16Results posted on the registry: Sumitomo Pharma America, Inc., APL-130277 + subcutaneous apomorphine (NCT03391882)
- 2022-12-14Results posted on the registry: Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-12-14Also stopped (terminated): Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision